RCT hospitalized patients testing viral load shortly after a single mouthwash with PVP-I, hydrogen peroxide, cetylpyridinium chloride, chlorhexidine, and water. For PVP-I, there were only 5 patients with viable virus at baseline. Cross-treatment comparisons are limited due to the very small sample sizes and large difference between baseline viral loads (the baseline viral culture non-log copies/mL was ~10,000 times higher in the water group vs. PVP-I).
The trial registration shows that 160 patients were recruited, with 62 patients added in an October 6, 2021 change, however the paper presents results for only 75 patients.
Sánchez Barrueco et al., 7/27/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, mean age 55.0, 17 authors, trial NCT04707742 (history)